Type I interferon as determinant of autoantibody production in primary Sjogren’s syndrome and systemic lupus erythematosus
- Prosjektnummer
- SFP916-10
- Ansvarlig person
- Johannes Nossent
- Institusjon
- Universitetet i Tromsø
- Prosjektkategori
- Postdoktorstipend
- Helsekategori
- Inflammatory and immune system
- Forskningsaktivitet
- 2. Aetiology
Interferon-Alpha Activation in Relation to Pro-Inflammatory Cytokines and Anti-Ro/La Response in Primary Sjøgren’s Syndrome
2011 ACR/ARHP Annual Scientific Meeting ; poster, published in Arthr Rheum 2011 supll
Low Copy Number of Fcgamma Receptor 3B Gene Is a Disease Susceptibility and Severity Factor in Primary Sjøgren’s Syndrome
2011 ACR/ARHP Annual Scientific Meeting ; poster, published in Arthr Rheum 2011 supll
Increased interferon-alpha levels in primary Sjøgren's syndrome: frequency and relationship with pro-inflammatory cytokines, cli
5th Autoimmunity Congress Asia, Singapore, 17-19 November 2011- oral presentation; published in Arthr Rheum 2011 supll
Low copy number of Fcgammareceptor IIIB predisposes to both Sjøgren's syndrome and SLE, but contributes to disease through diffe
The 1st Symposium of the Asia Pacific League of Associations for Rheumatology- oral presentation 15-17 April, 2011 in Taipei, Taiwan, publisert i The International Journal of Rheumatic Diseases 2011 supll
Low copy number of Fcgammareceptor IIIB predisposes to Sjogren's syndrome as well as SLE, but contributes to disease through dif
Australian Rheumatology Association 52nd Annual Scientific Meeting14 – 17 May 2011, Brisbane Convention and Exhibition Centre, Queensland oral presentation International Journal of Medicine,2011 supll
Organ damage in SLE: prevalence, risk and immunological biomarkers
- Disputert:
- august 2010
- Hovedveileder:
- J Nossent
eRapport er utarbeidet av Sølvi Lerfald og Reidar Thorstensen, Regionalt kompetansesenter for klinisk forskning, Helse Vest RHF, og videreutvikles av de fire RHF-ene i fellesskap, med støtte fra Helse Vest IKT
Alle henvendelser rettes til eRapport, Helse Nord